Duz, Senem ArdaMumcu, AkinDogan, BeratYilmaz, ErcanCoskun, Ebru InciSaridogan, ErdincTuncay, Gorkem2024-08-042024-08-0420220932-00671432-0711https://doi.org/10.1007/s00404-022-06587-0https://hdl.handle.net/11616/100650Purpose To analyze endometrial metabolite profiles between patients with endometrial cancer and controls. Methods Seventeen (17) women with endometrium cancer and 18 controls were enrolled in this study. H-1 HR-MAS (High Resolution-Magic Angle Spinning) NMR (Nuclear Magnetic Resonance) spectroscopy data obtained from endometrial tissue samples of patients with endometrial cancer and control group were analyzed with bioinformatics methods. Results Principal component analysis (PCA) and the partial least squares discriminant analysis (PLS-DA) score plots obtained with the multivariate statistical analysis of pre-processed spectral data shows a separation between the samples from patients with endometrial cancer and controls. Analysis results suggest that the levels of lactate, glucose, o-phosphoethanolamine, choline, glycerophosphocholine, phosphocholine, leucine, isoleucine, valine, glutamate, glutamine, n-acetyltyrosine, methionine, taurine, alanine, aspartate and phenylalanine are increased in patients with endometrial cancer compared to the controls. Conclusion The metabolomics signature of patients with endometrial cancer is different from that of benign endometrial tissue.eninfo:eu-repo/semantics/closedAccessEndometrial cancerEndometrial tissueH-1-NMRMetabolomicsArticle3066215521663556763510.1007/s00404-022-06587-02-s2.0-85130130007Q2WOS:000795622500001Q3